Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loxapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 7/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 11/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | HRH2 | P25021 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loxapine SCHEMBL19386241 | 1.00 | HRH4 (1.00) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL94146 | 1.00 | HRH4 (1.00) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL30324780 | 1.00 | HRH4 (1.00) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL29482385 | 1.00 | HRH4 (1.00) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL41625 | 0.99 | HRH4 (0.98) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL30903930 | 0.99 | HRH4 (0.98) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL4164270 | 0.99 | HRH4 (0.98) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL3674535 | 0.98 | HRH4 (0.95) | HRH4DRD2DRD4DRD3CHRM1 | |
| SCHEMBL7410631 | 0.91 | HRH4 (0.84) | HRH4DRD2DRD4DRD3CHRM1 | |
| Loxapine SCHEMBL5500954 | 0.90 | LMNA (1.00) | HRH4DRD2DRD4DRD3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| US-20250325521-A1 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | BIOXCEL THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12410474-B2 | Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient | NORTHWESTERN UNIVERSITY (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| EP-4577246-A1 | DENDRIMER CONJUGATES OF ANTIDEPRESSANT AND ANTIPSYCHOTIC AGENTS AND THEIR METHODS OF USE | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044760-A9 | DENDRIMER CONJUGATES OF ANTIDEPRESSANT AND ANTIPSYCHOTIC AGENTS AND THEIR METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240408325-A1 | HANDHELD MEDICAL DEVICE WITH IMPROVED DELIVERY OF AEROSOL PARTICLES | ALEXZA PHARMACEUTICALS, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4448067-A1 | METHODS AND DEVICES FOR CONTROLLING THE TEMPERATURE OF A DRUG FOIL SUBSTRATE TO GENERATE AN AEROSOL | Alexza Pharmaceuticals, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4447937-A1 | HANDHELD MEDICAL DEVICE WITH IMPROVED DELIVERY OF AEROSOL PARTICLES | Alexza Pharmaceuticals, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240324679-A1 | METHODS AND DEVICES FOR CONTROLLING THE TEMPERATURE OF A DRUG FOIL SUBSTRATE TO GENERATE AN AEROSOL | ALEXZA PHARMACEUTICALS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| EP-4135741-A1 | SYNTHETIC PEPTIDES FOR MODULATING THE METABOTROPIC GLUTAMATE RECEPTOR 5 | Lactocore, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11518755-B2 | Stable solutions of multicyclic antidepressants | LEYDEN TECHNOLOGIES B.V. (NL) | 2022-12-06 | — | — | US | disclosed |
| EP-4087552-A1 | COGNITIVE DISORDER PREVENTION AND THERAPY | Aneurotech IP BV (BE) | 2022-11-16 | — | — | EP | disclosed |
| CN-115279356-A | Prevention and treatment of cognitive disorders | 安尤罗泰克IP私人有限公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-4017524-A1 | COMPOSITIONS COMPRISING HYALURONIDASE AND/OR COLLAGENASE AND/OR 4-METHYLUMBELLIFERONE (4-MU) AND METHODS OF TREATMENT USING SAME | Standard of Care Corporation (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20220183965-A1 | INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICE | ALTER DOMUS (US) LLC | 2022-06-16 | — | — | US | disclosed |
| US-20220177970-A1 | METHODS, KITS, AND DEVICES FOR DIAGNOSING, PROGNOSING, AND TREATING PSYCHIATRIC DISORDERS IN A PATIENT | NORTHWESTERN UNIVERSITY | 2022-06-09 | — | — | US | disclosed |
| US-20220139517-A1 | Service for Coordinating Monitoring of REMS Medications | DUFFY PAUL (US) | 2022-05-05 | — | — | US | disclosed |
| US-11278492-B2 | Intranasal delivery of olanzapine by precision olfactory device | IMPEL NEUROPHARMA, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220031663-A1 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | OAKTREE FUND ADMINISTRATION, LLC | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518755-B2 | Stable solutions of multicyclic antidepressants | TPH1, BDNF, TPH2 | DRD2 27/4885DRD4 16/4885DRD3 28/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | DRD2 11/4885DRD4 17/4885DRD3 26/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | DRD2 4318/4885DRD4 4407/4885DRD3 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.